Ultragenyx Pharmaceutical Inc. (RARE)

Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

JAGUAR URANIUM REPORTS RARE EARTH OXIDES ASSOCIATED WITH URANIUM-PHOSPHATE-VANADIUM MINERALIZATION AT THE BERLIN ASSET IN COLOMBIA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

ULTRA-RARE MCA CENTENAIRE, MONACO'S FIRST SUPERCAR, OFFERED AT BROAD ARROW'S 2026 ZOUTE CONCOURS AUCTION

RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?

Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

US FDA approves Ultragenyx's gene therapy for rare disorder